SARMs in Breast Cancer

Because enobosarm targets the androgen receptor, but is non-steroidal, it cannot be converted to other hormones by common enzymes, and therefore does not cause effects in other hormone systems in the same way that other androgens and steroids do.

Enobosarm has been evaluated in two types of breast cancer patients:

  • women whose tumors are estrogen and androgen receptor positive
  • women with androgen receptor positive but triple negative (estrogen, progesterone and HER2 negative) breast cancer